Monday, September 04, 2023 7:32:48 PM
Yes, the original study took many years because they captured OS data and participants lived long, but any studies following commercialization could be much more swift.
DCVax-L has such a solid safety profile—I think that it can move rapidly through clinical investigations for other cancers once it is initially approved for GBM.
This was another insightful idea that was sparked by learningcurve2020’s comment yesterday about the possibility of future combinations with
DCVax-L
https://www.urotoday.com/video-lectures/asco-gu-2023/video/3244-new-nci-fda-unit-aims-to-streamline-drug-development-for-cancer-patients-michael-morris.html
https://www.jci.org/articles/view/169314
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
